

# Ana Vivancos

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8564280/publications.pdf>

Version: 2024-02-01

121  
papers

6,774  
citations

94433

37  
h-index

62596

80  
g-index

122  
all docs

122  
docs citations

122  
times ranked

13392  
citing authors

#	ARTICLE	IF	CITATIONS
1	High <i>FGFR1</i> mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 137-149.	7.0	12
2	The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology. <i>Nature Cancer</i> , 2022, 3, 251-261.	13.2	44
3	High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC. , 2022, 10, e004197.		5
4	Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic Prostate Cancer Following Progression on Androgen-Targeting Therapies. <i>JCO Precision Oncology</i> , 2022, , .	3.0	10
5	Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancer. <i>Molecular Oncology</i> , 2021, 15, 887-900.	4.6	24
6	MYC Copy Number Detection in Clinical Samples Using a Digital DNA-Hybridization and Detection Method. <i>Methods in Molecular Biology</i> , 2021, 2318, 321-336.	0.9	0
7	Combined Analysis of Concordance between Liquid and Tumor Tissue Biopsies for <i>RAS</i> Mutations in Colorectal Cancer with a Single Metastasis Site: The METABEAM Study. <i>Clinical Cancer Research</i> , 2021, 27, 2515-2522.	7.0	39
8	Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5818-5827.	7.0	14
9	Case Report: A Case Study Documenting the Activity of Atezolizumab in a PD-L1-Negative Triple-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 710596.	2.8	5
10	Genetic evolution to tyrosine kinase inhibitory therapy in patients with EGFR-mutated non-small-cell lung cancer. <i>British Journal of Cancer</i> , 2021, 125, 1561-1569.	6.4	4
11	First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study. <i>Frontiers in Oncology</i> , 2021, 11, 744112.	2.8	3
12	Identification of Expression Profiles Defining Distinct Prognostic Subsets of Radioactive-Iodine Refractory Differentiated Thyroid Cancer from the DECISION Trial. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 312-317.	4.1	8
13	Long duration of immunotherapy in a <i>STK11</i> mutated/ <i>KRAS</i> wild-type non-small cell lung cancer patient. <i>Pulmonology</i> , 2020, 26, 49-50.	2.1	8
14	Epigenetic <i>EGFR</i> Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine Carcinomas. <i>Clinical Cancer Research</i> , 2020, 26, 902-909.	7.0	29
15	Evolving Landscape of Molecular Prescreening Strategies for Oncology Early Clinical Trials. <i>JCO Precision Oncology</i> , 2020, 4, 505-513.	3.0	10
16	Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal. <i>Nature Medicine</i> , 2020, 26, 992-994.	30.7	56
17	Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors. <i>BMC Cancer</i> , 2020, 20, 99.	2.6	31
18	Abstract 2953: Adapting a molecular prescreening program to detect notch pathway alterations in the context of early drug development. , 2020, , .		0

#	ARTICLE	IF	CITATIONS
19	Abstract 2488: Characterization of gene fusions in paired primary and metastatic samples of breast cancer in the AURORA molecular screening program. , 2020, , .		0
20	Impact of circulating tumor DNA mutant allele fraction on prognosis in <i>RAS</i> -mutant metastatic colorectal cancer. <i>Molecular Oncology</i> , 2019, 13, 1827-1835.	4.6	40
21	Targeted multiplex proteomics for molecular prescreening and biomarker discovery in metastatic colorectal cancer. <i>Scientific Reports</i> , 2019, 9, 13568.	3.3	14
22	RNF43- and NOTCH1-Mutated Chemotherapy and Anti-EGFR-Refractory Colorectal Cancer: Should Clonality Guide Target Prioritization With Investigational Therapies?. <i>JCO Precision Oncology</i> , 2019, 3, 1-3.	3.0	1
23	Comparison of the Clinical Sensitivity of the Idylla Platform and the OncoBEAM RAS CRC Assay for KRAS Mutation Detection in Liquid Biopsy Samples. <i>Scientific Reports</i> , 2019, 9, 8976.	3.3	34
24	Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer. <i>ESMO Open</i> , 2019, 4, e000444.	4.5	8
25	Clinicopathological and Molecular Characterization of Metastatic Gastrointestinal Stromal Tumors with Prolonged Benefit to Frontline Imatinib. <i>Oncologist</i> , 2019, 24, 680-687.	3.7	7
26	Activity of HSP90 Inhibitor in a Metastatic Lung Cancer Patient With a Germline BRCA1 Mutation. <i>Journal of the National Cancer Institute</i> , 2018, 110, 914-917.	6.3	16
27	Molecular Diagnosis of Diffuse Gliomas through Sequencing of Cell-Free Circulating Tumor DNA from Cerebrospinal Fluid. <i>Clinical Cancer Research</i> , 2018, 24, 2812-2819.	7.0	128
28	RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer. <i>Annals of Oncology</i> , 2018, 29, 1203-1210.	1.2	280
29	Early evolutionary divergence between papillary and anaplastic thyroid cancers. <i>Annals of Oncology</i> , 2018, 29, 1454-1460.	1.2	44
30	Circulating cell-free DNA as predictor of treatment failure after neoadjuvant chemoradiotherapy before surgery in patients with locally advanced rectal cancer: is it ready for primetime?. <i>Annals of Oncology</i> , 2018, 29, 532-534.	1.2	5
31	Genetic Profiles of Squamous Cell Carcinomas Associated with Recessive Dystrophic Epidermolysis Bullosa Unveil NOTCH and TP53 Mutations and an Increased MYC Expression. <i>Journal of Investigative Dermatology</i> , 2018, 138, 1423-1427.	0.7	2
32	Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations. <i>Genome Medicine</i> , 2018, 10, 25.	8.2	366
33	An evaluation of the challenges to developing tumor BRCA1 and BRCA2 testing methodologies for clinical practice. <i>Human Mutation</i> , 2018, 39, 394-405.	2.5	24
34	Multicenter Phase II Study of Lurbinectedin in <i>BRCA</i> -Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy. <i>Journal of Clinical Oncology</i> , 2018, 36, 3134-3143.	1.6	43
35	Multiple primary cancers (MPC) in a series of lung cancer (LC) patient: Incidence and outcome. <i>Annals of Oncology</i> , 2018, 29, viii641.	1.2	0
36	Evaluation of the sensitivity of RAS mutation detection of the Idylla platform in comparison to the OncoBEAM RAS CRC assay. <i>Annals of Oncology</i> , 2018, 29, viii184.	1.2	0

#	ARTICLE	IF	CITATIONS
37	Primary results of the first nationwide molecular screening program in Spain for patients with advanced breast cancer (AGATA SOLTI-1301 study). <i>Annals of Oncology</i> , 2018, 29, viii90.	1.2	0
38	Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2018, 119, 1464-1470.	6.4	62
39	Multigene panel testing beyond BRCA1/2 in breast/ovarian cancer Spanish families and clinical actionability of findings. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 2495-2513.	2.5	53
40	TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence. <i>Journal of Clinical Investigation</i> , 2018, 128, 3887-3905.	8.2	79
41	Regional and subtype-dependent miRNA signatures in sporadic Creutzfeldt-Jakob disease are accompanied by alterations in miRNA silencing machinery and biogenesis. <i>PLoS Pathogens</i> , 2018, 14, e1006802.	4.7	26
42	Abstract B075: Evolving molecular prescreening program to identify genomic alterations in the NOTCH pathway. , 2018, , .		0
43	Concordance of genomic alterations (GA) in synchronous tumor biopsies (tBx) and circulating tumor (ct) DNA from metastatic breast cancer (MBC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2018, 36, 1073-1073.	1.6	7
44	Single-cell transcriptome conservation in cryopreserved cells and tissues. <i>Genome Biology</i> , 2017, 18, 45.	8.8	134
45	Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-“Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma. <i>Cancer Research</i> , 2017, 77, 3540-3550.	0.9	327
46	Analysis of mutant allele fractions in driver genes in colorectal cancer “ biological and clinical insights. <i>Molecular Oncology</i> , 2017, 11, 1263-1272.	4.6	26
47	Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer. <i>Annals of Oncology</i> , 2017, 28, 1294-1301.	1.2	150
48	DualMET andERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC). <i>Annals of Oncology</i> , 2017, 28, 2451-2457.	1.2	58
49	Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action. <i>Targeted Oncology</i> , 2017, 12, 19-35.	3.6	77
50	Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review. <i>Annals of Oncology</i> , 2017, 28, 2943-2949.	1.2	89
51	Pancreatic cancer heterogeneity and response to Mek inhibition. <i>Oncogene</i> , 2017, 36, 5639-5647.	5.9	19
52	Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer. <i>Oncotarget</i> , 2017, 8, 21930-21937.	1.8	17
53	Outcome of <i>KRAS</i> mutated (m) non-small cell lung cancer (NSCLC) patients (pts) treated with immune checkpoint inhibitors (immuneCI).. <i>Journal of Clinical Oncology</i> , 2017, 35, e20526-e20526.	1.6	0
54	Molecular sequencing and gene fusion detection in non-small cell lung cancer (NSCLC) patients: Impact of co-existing alterations.. <i>Journal of Clinical Oncology</i> , 2017, 35, e23103-e23103.	1.6	0

#	ARTICLE	IF	CITATIONS
55	RNAseq analysis of the sorafenib phase III DECISION trial in differentiated thyroid cancer (DTC): Correlation with clinical outcome.. Journal of Clinical Oncology, 2017, 35, 6083-6083.	1.6	1
56	Molecular, clinical and prognostic characterization of double KRAS/PIK3CA (dKP) mutated metastatic colorectal cancer (mCRC). Annals of Oncology, 2016, 27, vi185.	1.2	1
57	Molecular screening programmes for precision medicine: lessons learned from personalized medicine trials. Expert Review of Precision Medicine and Drug Development, 2016, 1, 419-430.	0.7	1
58	Prognostic impact of KRAS mutation in metastatic (met) pancreatic cancer patients (pts). Annals of Oncology, 2016, 27, vi232.	1.2	0
59	Spatiotemporal Control of Forkhead Binding to DNA Regulates the Meiotic Gene Expression Program. Cell Reports, 2016, 14, 885-895.	6.4	12
60	Genetic evolution of nevus of Ota reveals clonal heterogeneity acquiring BAP1 and TP53 mutations. Pigment Cell and Melanoma Research, 2016, 29, 247-253.	3.3	18
61	The homeoprotein SIX1 controls cellular senescence through the regulation of p16INK4A and differentiation-related genes. Oncogene, 2016, 35, 3485-3494.	5.9	15
62	Tankyrase Inhibition Blocks Wnt/ $\beta$ -Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer. Clinical Cancer Research, 2016, 22, 644-656.	7.0	143
63	Matching degree between PI3K/AKT/mTOR (PAM) pathway mutations (mut) and therapy (ttx) as predictor of clinical benefit (ClinBen) in early trials.. Journal of Clinical Oncology, 2016, 34, 2572-2572.	1.6	2
64	Comprehensive profiling of biliary tract cancers (BTC) to reveal molecular heterogeneity with implications for matched targeted therapies (MTT).. Journal of Clinical Oncology, 2016, 34, 4085-4085.	1.6	3
65	Impact of molecular prescreening for genomically-guided trials in head and neck cancer (HNC).. Journal of Clinical Oncology, 2016, 34, 6030-6030.	1.6	1
66	Prognostic impact of primary tumor site location in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2016, 34, 578-578.	1.6	2
67	Survival determinants with matched targeted therapies in BRAF mutant metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2016, 34, 649-649.	1.6	1
68	Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology. Oncotarget, 2016, 7, 22543-22555.	1.8	11
69	Genetic profile of GNAQ-mutated blue melanocytic neoplasms reveals mutations in genes linked to genomic instability and the PI3K pathway. Oncotarget, 2016, 7, 28086-28095.	1.8	16
70	Molecular prescreening (MP) to treat patients (pts) with advanced pancreatic cancer (PC) in early clinical trials.. Journal of Clinical Oncology, 2016, 34, 272-272.	1.6	0
71	Abstract P2-08-13: Integrating multiplex and next generation sequencing (NGS) platforms in routine molecular profiling of metastatic breast cancer (MBC) patients (pts): Trends for enrollment in genotype-directed clinical trials (GDTs)., 2016, , .		0
72	Outcome of RAS mutated lung adenocarcinoma (ADC ) patients (pts) on standard chemotherapy (chemo) and immune checkpoint inhibitors (immuneCI).. Journal of Clinical Oncology, 2016, 34, e20597-e20597.	1.6	0

#	ARTICLE	IF	CITATIONS
73	Clonality of PIK3CA mutations (mut) and efficacy of PI3K/AKT/mTOR inhibitors (PAMi) in patients (pts) with metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2016, 34, 528-528.	1.6	3
74	Association of response to programmed death 1 receptor or ligand (PD1/PDL1) blockade with immune-related gene expression profiling across three cancer-types.. Journal of Clinical Oncology, 2016, 34, 3038-3038.	1.6	0
75	Analysis of <i>RSPO</i> gene expression in solid tumors.. Journal of Clinical Oncology, 2016, 34, e23235-e23235.	1.6	1
76	Clonality patterns of driver mutations (mut) to reveal spatial-temporal genomic heterogeneity in colorectal cancer (CRC).. Journal of Clinical Oncology, 2016, 34, 3509-3509.	1.6	0
77	2399 Impact of KRAS mutations on clinical outcomes in advanced refractory pancreatic cancer patients. European Journal of Cancer, 2015, 51, S470.	2.8	0
78	Mutational load by targeted next generation sequencing (NGS) panels as potential biomarker of response to checkpoint inhibitors. Annals of Oncology, 2015, 26, viii5.	1.2	0
79	AGATA molecular screening program: implementing precision medicine in patients with advanced breast cancer in Spain. Annals of Oncology, 2015, 26, ii21.	1.2	0
80	Identification of somatic gene mutations in penile squamous cell carcinoma. Genes Chromosomes and Cancer, 2015, 54, 629-637.	2.8	17
81	Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nature Communications, 2015, 6, 8839.	12.8	605
82	Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nature Medicine, 2015, 21, 560-562.	30.7	1,280
83	MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by <i>TP53</i> Mutation in Preclinical Models of Colorectal Cancer. Clinical Cancer Research, 2015, 21, 5499-5510.	7.0	18
84	Defining a minimal cell: essentiality of small ORFs and ncRNAs in a genome-reduced bacterium. Molecular Systems Biology, 2015, 11, 780.	7.2	133
85	Outcome evolution of matched molecular targeted agents (MTAs) in metastatic colorectal cancer (CRC) patients (pts): VHIO experience.. Journal of Clinical Oncology, 2015, 33, 3602-3602.	1.6	1
86	Clinical and molecular characterization of refractory BRAF mutant metastatic colorectal carcinoma (mCRC): Vall d'Hebron Institute of Oncology phase I program cohort.. Journal of Clinical Oncology, 2015, 33, 587-587.	1.6	0
87	Early drug development in advanced gynecologic cancer based on genetic tumor profiling.. Journal of Clinical Oncology, 2015, 33, 5562-5562.	1.6	0
88	Knocking on molecular alterations in advanced gastric cancer (AGC).. Journal of Clinical Oncology, 2015, 33, 4063-4063.	1.6	0
89	Abstract 930: Analysis of cell-free tumor DNA in cerebrospinal fluid to characterize and monitor the genetic alterations of brain tumors. Cancer Research, 2015, 75, 930-930.	0.9	2
90	Abstract LB-123: Analysis of cell-free plasma DNA (cfDNA) identifies 3 molecular subtypes of acquired resistance to AZD9291, a novel EGFR tyrosine kinase inhibitor (TKI), in patients (pts) with advanced lung cancer. , 2015, , .		0

#	ARTICLE	IF	CITATIONS
91	A Mouse Model Uncovers LKB1 as an UVB-Induced DNA Damage Sensor Mediating CDKN1A (p21WAF1/CIP1) Degradation. <i>PLoS Genetics</i> , 2014, 10, e1004721.	3.5	40
92	New approach to cancer therapy based on a molecularly defined cancer classification. <i>Ca-A Cancer Journal for Clinicians</i> , 2014, 64, 70-74.	329.8	22
93	Reprogramming activity of NANOGP8, a NANOG family member widely expressed in cancer. <i>Oncogene</i> , 2014, 33, 2513-2519.	5.9	37
94	Coexisting KRAS and PIK3CA exon 20 mutations as a potential poor-prognosis factor in metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 3591-3591.	1.6	0
95	Incorporation of FGFR1 and FGFR2 amplification status determination in routine molecular prescreening for targeted therapies.. <i>Journal of Clinical Oncology</i> , 2014, 32, 11105-11105.	1.6	0
96	Microarray and deep sequencing cross-platform analysis of the mirNome and isomiR variation in response to epidermal growth factor. <i>BMC Genomics</i> , 2013, 14, 371.	2.8	33
97	Circulating tumour cells and cell-free DNA as tools for managing breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 377-389.	27.6	164
98	Clinical Response to a Lapatinib-Based Therapy for a Li-Fraumeni Syndrome Patient with a Novel <i>HER2-V659E</i> Mutation. <i>Cancer Discovery</i> , 2013, 3, 1238-1244.	9.4	43
99	A Personalized Preclinical Model to Evaluate the Metastatic Potential of Patient-Derived Colon Cancer Initiating Cells. <i>Clinical Cancer Research</i> , 2013, 19, 6787-6801.	7.0	80
100	Genomic Analyses across Six Cancer Types Identify Basal-like Breast Cancer as a Unique Molecular Entity. <i>Scientific Reports</i> , 2013, 3, 3544.	3.3	45
101	Abstract C114: Clinical response to a lapatinib-based therapy of a Li-Fraumeni Syndrome patient with a novel <i>HER2-V659E</i> mutation.. , 2013, , .		0
102	Molecular prescreening to select patient population in early clinical trials. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 359-366.	27.6	68
103	Transcription start site associated RNAs in bacteria. <i>Molecular Systems Biology</i> , 2012, 8, 585.	7.2	40
104	687 <i>Beta-catenin</i> Confers Resistance to PI3K and AKT Inhibitors and Subverts <i>FOXO3a</i> to Promote Metastasis in Colon Cancer. <i>European Journal of Cancer</i> , 2012, 48, S162.	2.8	5
105	<i>β</i> -catenin confers resistance to PI3K and AKT inhibitors and subverts <i>FOXO3a</i> to promote metastasis in colon cancer. <i>Nature Medicine</i> , 2012, 18, 892-901.	30.7	336
106	Molecular Profiling of Patients with Colorectal Cancer and Matched Targeted Therapy in Phase I Clinical Trials. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 2062-2071.	4.1	77
107	Abstract 683: Evaluation of PTEN and PIK3CA status in breast cancer for patient selection: Cross-validation between institutions. , 2012, , .		0
108	Partial short-read sequencing of a highly inbred Iberian pig and genomics inference thereof. <i>Heredity</i> , 2011, 107, 256-264.	2.6	16

#	ARTICLE	IF	CITATIONS
109	Multiple platform assessment of the EGF dependent transcriptome by microarray and deep tag sequencing analysis. BMC Genomics, 2011, 12, 326.	2.8	19
110	Prognostic implications of phosphatidylinositol 3-kinase (PI3K) pathway alterations in metastatic triple-negative breast cancer (mTNBC).. Journal of Clinical Oncology, 2011, 29, 1081-1081.	1.6	0
111	Correlation between molecular features (MFs) and clinical results in endometrial cancer (EC): A single-institution experience.. Journal of Clinical Oncology, 2011, 29, e15572-e15572.	1.6	0
112	Lifespan extension by calorie restriction relies on the Sty1 MAP kinase stress pathway. EMBO Journal, 2010, 29, 981-991.	7.8	108
113	Strand-specific deep sequencing of the transcriptome. Genome Research, 2010, 20, 989-999.	5.5	76
114	C-terminal truncation of the peroxiredoxin Tpx1 decreases its sensitivity for hydrogen peroxide without compromising its role in signal transduction. Genes To Cells, 2008, 13, 171-179.	1.2	19
115	The Peroxiredoxin Tpx1 Is Essential as a H2O2 Scavenger during Aerobic Growth in Fission Yeast. Molecular Biology of the Cell, 2007, 18, 2288-2295.	2.1	54
116	EphB-ephrin-B interactions suppress colorectal cancer progression by compartmentalizing tumor cells. Nature Genetics, 2007, 39, 1376-1383.	21.4	242
117	Oxidative stress in Schizosaccharomyces pombe: different H2O2 levels, different response pathways. Molecular Genetics and Genomics, 2006, 276, 495-502.	2.1	98
118	A cysteine-sulfinic acid in peroxiredoxin regulates H2O2-sensing by the antioxidant Pap1 pathway. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 8875-8880.	7.1	230
119	The Glycolytic Metabolite Methylglyoxal Activates Pap1 and Sty1 Stress Responses in Schizosaccharomyces pombe. Journal of Biological Chemistry, 2005, 280, 36708-36713.	3.4	57
120	Activation of the redox sensor Pap1 by hydrogen peroxide requires modulation of the intracellular oxidant concentration. Molecular Microbiology, 2004, 52, 1427-1435.	2.5	104
121	Schizosaccharomyces pombe Cells Lacking the Ran-binding Protein Hba1 Show a Multidrug Resistance Phenotype Due to Constitutive Nuclear Accumulation of Pap1. Journal of Biological Chemistry, 2003, 278, 40565-40572.	3.4	36